Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity 131I-metaiodobenzylguanidine (131I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an app
[131I]-Metaiodobenzylguanidine in the treatment of metastatic neuroblastoma
✍ Scribed by Thomas Klingebiel; Jörn Treuner; Gerhard Ehninger; Klaus D. Keller; Roland Dopfer; Ullrich Feine; Dietrich Niethammer
- Publisher
- Springer
- Year
- 1989
- Tongue
- English
- Weight
- 656 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Poor results with 131I-meta-iodobenzylguanidine (MIBG) therapy have been obtained in two children with stage IV neuroblastoma treated after partial surgery and unsatisfactory combination chemotherapy. Both patients' response to treatment (four and three 1-month-spaced courses, respectively; cumulati
Background. Standard chemo-radiotherapy methods for the treatment of children with advanced neuroblastoma (NBL) including bone marrow transplant approaches have been disappointing. These poor results can be ascribed to the evolution of residual drug-resistant cell populations. Curative attempts shou
I-131-metaiodobenzylguanidine was used for treatment of neuroblastoma stage IV in three children after surgery and or chemotherapy had failed to be effective. In two of the children with multilocular lesions, after an impressive improvement of clinical symptoms tumor progression was observed. Becaus
## Abstract ## BACKGROUND ^131^I‐metaiodobenzylguanidine (^131^I‐MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with modera